Key facts for DRG 838
- FY2027 relative weight
- 2.1585
- Higher than 66% of all MS-DRGs
- Change vs FY2026
- +3.4%
- FY2026 weight 2.0874
- Geometric mean LOS
- 5.0 days
- Arithmetic mean 6.6 days
- MDC
- 17
- Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
- Severity level
- with CC (complication or comorbidity)
- National unadjusted operating payment
- $14,781.41
- Weight × $6,848.00 FY2027 standardized amount; capital adds $1,165.48
- Transfer policy
- Not a transfer DRG
TL;DR
MS-DRG 838 is a medical group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), at its family's CC level. CMS assigns it a FY2027 relative weight of 2.1585 with a geometric mean length of stay of 5.0 days and an arithmetic mean of 6.6. Its weight moved up 3.4% from FY2026 (2.0874). That weight is higher than 66% of all MS-DRGs. The v44 Definitions Manual assigns it through 3 chemotherapy (principal diagnosis) codes and 33 acute leukemia (secondary diagnosis) codes and 10 high dose chemo agent codes.
What changed from FY2026 to FY2027
CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 838 the FY2027 relative weight is 2.1585 against 2.0874 in FY2026, a rise of 3.41%, which exceeds the 2% threshold worth re-checking in contract models.
| Metric | FY2026 | FY2027 | Change |
|---|---|---|---|
| Relative weight | 2.0874 | 2.1585 | +0.0711 |
| Geometric mean LOS (days) | 5.1 | 5.0 | -0.1 |
| Arithmetic mean LOS (days) | 6.7 | 6.6 | -0.1 |
CC and MCC family
DRG 838 stands alone: CMS does not split this base group by CC or MCC severity, so complication documentation does not move the assignment, although it still affects quality and risk-adjustment reporting.
National unadjusted payment for DRG 838
Multiplying the FY2027 relative weight (2.1585) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. This group has no CC/MCC sibling, so the amount does not change with secondary-diagnosis capture.
| Component | National rate | DRG 838 |
|---|---|---|
| Operating (labor and nonlabor share) | $4,519.68 + $2,328.32 = $6,848.00 | $14,781.41 |
| Capital (federal rate) | $539.95 | $1,165.48 |
| Operating plus capital | $15,946.89 |
These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 838.
Risk-adjusting diagnoses in this DRG
Appendix B of the v44 Definitions Manual lists 36 ICD-10-CM codes in the logic for DRG 838; 33 of them also map to a CMS-HCC V28 payment category, across 3 categories. The same documentation that supports the inpatient group feeds Medicare Advantage risk adjustment when the patient is an MA enrollee.
| V28 HCC | Category | Shared codes | Examples |
|---|---|---|---|
| HCC 17 | Cancer Metastatic to Lung, Liver, Brain, and Other Organs; Acute Myeloid Leukemia Except Promyelocytic | 24 | C92.00, C92.01, C92.02 |
| HCC 18 | Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid | 6 | C91.00, C91.01, C91.02 |
| HCC 22 | Bladder, Colorectal, and Other Cancers | 3 | C92.40, C92.41, C92.42 |
Grouper logic (v44 Definitions Manual)
The manual's split table for Chemotherapy with Acute Leukemia As Secondary Diagnosis gives one row per combination of criteria and the MS-DRG it assigns. DRG 838 is assigned on 2 rows of the table, one for each qualifying combination.
Chemotherapy (Principal Diagnosis): 3 ICD-10-CM codes in this DRG's assignment logic.
| ICD-10-CM code | Description |
|---|---|
| Z08 | Encounter for follow-up examination after completed treatment for malignant neoplasm |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| Z51.12 | Encounter for antineoplastic immunotherapy |
Acute Leukemia (Secondary Diagnosis): 33 ICD-10-CM codes in this DRG's assignment logic; the first 12 are shown.
| ICD-10-CM code | Description |
|---|---|
| C91.00 | Acute lymphoblastic leukemia not having achieved remission |
| C91.01 | Acute lymphoblastic leukemia, in remission |
| C91.02 | Acute lymphoblastic leukemia, in relapse |
| C92.00 | Acute myeloblastic leukemia, not having achieved remission |
| C92.01 | Acute myeloblastic leukemia, in remission |
| C92.02 | Acute myeloblastic leukemia, in relapse |
| C92.40 | Acute promyelocytic leukemia, not having achieved remission |
| C92.41 | Acute promyelocytic leukemia, in remission |
| C92.42 | Acute promyelocytic leukemia, in relapse |
| C92.50 | Acute myelomonocytic leukemia, not having achieved remission |
| C92.51 | Acute myelomonocytic leukemia, in remission |
| C92.52 | Acute myelomonocytic leukemia, in relapse |
High Dose Chemo Agent: 10 ICD-10-PCS codes in this DRG's assignment logic.
| ICD-10-PCS code | Description |
|---|---|
| 3E03002 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach |
| 3E03302 | Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach |
| 3E04002 | Introduction of High-dose Interleukin-2 into Central Vein, Open Approach |
| 3E04302 | Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach |
| 3E05002 | Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach |
| 3E05302 | Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach |
| 3E06002 | Introduction of High-dose Interleukin-2 into Central Artery, Open Approach |
| 3E06302 | Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach |
| 3E0R302 | Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach |
| 3E0S302 | Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach |
Code editor, HAC and CC/MCC exclusion notes for DRG 838
Table 6K part 3 excludes 33 secondary diagnoses from acting as a CC or MCC in MS-DRGs 837-839 (Chemotherapy with Acute Leukemia as Secondary Diagnosis or with High Dose Chemotherapy Agent), because they are part of the group's own logic: C91.00, C91.01, C91.02, C92.00 and others. On a stay in this family they do not move it to the with-CC or with-MCC member; the CC/MCC list shows every family with such exclusions.
The Definitions Manual lists the diagnosis and procedure codes that lead to DRG 838; these are the ones that are also on a Medicare Code Editor list and can draw that edit.
Documentation and denial exposure
As a medical DRG, assignment depends on the principal diagnosis sequenced from the attending's documentation; a secondary condition sequenced first, or a symptom code in place of the confirmed diagnosis, changes the MDC or the DRG. Because this family has no severity split, review risk concentrates on medical-necessity of the admission itself and on the two-midnight benchmark. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).
For teams evaluating QuickIntell software
Evaluate a documentation and coding workflow for DRG 838
Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — DRG 838
What is MS-DRG 838?
MS-DRG 838 is "Chemotherapy with Acute Leukemia as Secondary Diagnosis with CC or High Dose Chemotherapy Agent", a medical Medicare Severity Diagnosis-Related Group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.
What is the FY2027 relative weight for DRG 838?
The FY2027 relative weight is 2.1585 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 2.0874, a change of +3.4%.
What is the Medicare base payment for MS-DRG 838?
$14,781.41 for operating costs plus $1,165.48 for capital, $15,946.89 together, at the FY2027 national rates: weight 2.1585 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.
What is the average length of stay for DRG 838?
CMS reports a geometric mean length of stay of 5.0 days and an arithmetic mean of 6.6 days for FY2027. The geometric mean is used for transfer-payment calculations.
What documentation supports the severity level of DRG 838?
DRG 838 is reached when the stay carries a secondary diagnosis from the CMS Complication or Comorbidity list but none from the MCC list. Common CC captures include chronic kidney disease stage 3 and above, uncontrolled diabetes with manifestations, malnutrition of specified severity and heart failure of a stated type. Each must be documented by the treating clinician and show clinical relevance in the record; a condition listed only in the problem list without assessment is the most frequent reason a CC is removed on audit and the stay drops to the base DRG.
Which codes group to DRG 838?
The v44 Definitions Manual lists 3 chemotherapy (principal diagnosis) codes and 33 acute leukemia (secondary diagnosis) codes and 10 high dose chemo agent codes for this group. Examples from the chemotherapy (principal diagnosis) list, Z08 (Encounter for follow-up examination after completed treatment for malignant neoplasm); Z51.11 (Encounter for antineoplastic chemotherapy); and from the acute leukemia (secondary diagnosis) list, C92.40 (Acute promyelocytic leukemia, not having achieved remission); C92.41 (Acute promyelocytic leukemia, in remission).
Is DRG 838 a post-acute transfer DRG?
No. DRG 838 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- IPPS FY2027 Table 5 as corrected by correction notice CMS-1849-CN3Version v44 FY2027 (final rule + CN3) · effective 2026-10-01 · file CMS-1849-CN Table 5.txtSHA-256 2cc4e0b083e62e40…
- IPPS FY2026 Final Rule Table 5 (CMS-1833-F)Version v43 FY2026 · effective 2025-10-01 · file CMS-1833-F Table 5.txtSHA-256 bf8c390d14b3cd3e…
- ICD-10 MS-DRG Definitions Manual v44 (text)Version v44 · effective 2026-10-01 · file fy2027-fr-icd10-ms-drg-definitions-manual-files-v44.zipSHA-256 ae4f6c11727fe91f…
Disclaimer
This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.